Logo (Merck) 351 Pill - yellow oval
Generic Name: vorapaxar
Pill with imprint Logo (Merck) 351 is Yellow, Oval and has been identified as Zontivity vorapaxar sulfate 2.5 mg (2.08 mg base). It is supplied by Merck Sharp & Dohme Corp.
Zontivity is used in the treatment of Peripheral Arterial Disease; Prevention of Atherothrombotic Events; Thromboembolic Disorder and belongs to the drug class protease-activated receptor-1 antagonists. There is no proven risk in humans during pregnancy. Zontivity vorapaxar sulfate 2.5 mg (2.08 mg base) is not a controlled substance under the Controlled Substances Act (CSA).
Images for Logo (Merck) 351
Zontivity
- Generic Name
- vorapaxar
- Imprint
- Logo (Merck) 351
- Strength
- vorapaxar sulfate 2.5 mg (2.08 mg base)
- Color
- Yellow
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Protease-activated receptor-1 antagonists
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Merck Sharp & Dohme Corp.
- National Drug Code (NDC)
- 00006-0351 (Discontinued)
- Inactive Ingredients
-
lactose monohydrate,
microcrystalline cellulose,
croscarmellose sodium,
povidone,
magnesium stearate,
hypromellose 2910 (15 mPa.s),
titanium dioxide,
triacetin,
ferric oxide yellow
Note: Inactive ingredients may vary.
See also:
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Plavix
Plavix (clopidogrel) is used to prevent blood clots after a recent heart attack or stroke. Includes ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Rivaroxaban
Rivaroxaban is used for atrial fibrillation, cardiovascular risk reduction, congenital heart ...
Clopidogrel
Clopidogrel is used for acute coronary syndrome, acute coronary syndrome, prophylaxis, heart ...
More about Zontivity (vorapaxar)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: protease-activated receptor-1 antagonists
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.